| ID | 67508 |
| FullText URL | |
| Author |
Nagao, Shoji
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Nishio, Shin
Department of Obstetrics and Gynecology, Kurume University School of Medicine
Takehara, Kazuhiro
Department of Gynecologic Oncology, NHO Shikoku Cancer Center
Sato, Shinya
Department of Obstetrics and Gynecology, Tottori University
Satoh, Toyomi
Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba
Shimada, Muneaki
Department of Gynecology, Tohoku University Hospital
Yamaguchi, Satoshi
Department of Medical Oncology, Hyogo Cancer Center
Tanabe, Hiroshi
Department of Obstetrics and Gynecology, Jikei University School of Medicine
Takano, Masashi
Department of Obstetrics and Gynecology, National Defense Medical College
Horie, Kouji
Department of Gynecologic Oncology, Saitama Cancer Center
Takei, Yuji
Department of Obstetrics and Gynecology, Jichi Medical University
Imai, Yuichi
Department of Obstetrics and Gynecology, Yokohama City University Hospital
Hibino, Yumi
Department of Gynecologic Oncology, NHO Shikoku Cancer Center
Hasegawa, Kosei
Department of Gynecologic Oncology, Saitama Medical University International Medical Center
Takekuma, Munetaka
Department of Gynecology, Shizuoka Cancer Center
Nakamura, Kazuto
Department of Gynecology, Gunma Prefectural Cancer Center
Takano, Hirokuni
Department of Obstetrics and Gynecology, Jikei University School of Medicine
Fujiwara, Keiichi
Department of Gynecologic Oncology, Saitama Medical University International Medical Center
Masuyama, Hisashi
Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kaken ID
publons
researchmap
|
| Abstract | Background We previously demonstrated the applicability of the concept of “platinum sensitivity” in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the debate continues regarding treatment options in patients with recurrent endometrial cancer who have previously received platinum-based chemotherapy. In this study, we assessed the duration of response to secondary platinum-based treatment using pooled data from the SGSG-012/GOTIC-004/Intergroup study.
Methods Among the 279 participants in the SGSG-012/GOTIC-004/Intergroup study wherein platinum-based chemotherapy was re-administered for managing recurrent endometrial cancer between January 2005 and December 2009, 130 (47%) responded to chemotherapy. We compared the relationship between platinum-free interval and duration of secondary platinum-based treatment using pooled data. Results In 40 patients (31%), the duration of response to secondary platinum-based treatment exceeded the platinum-free interval. The duration of response to secondary platinum-based treatment exceeded 12 months in 51 patients (39%) [platinum-free interval: < 12 months, 14/48 (29%); 12–23 months, 18/43 (42%); 24–35 months, 8/19 (42%); ≥ 36 months, 11/20 (55%)]. In particular, in eight patients (6%), the duration of response to secondary platinum-based treatment exceeded 36 months [platinum-free interval: < 12 months, 3/48 (6%); 12–23 months, 0/19 (0%); 24–35 months, 2/19 (11%); ≥ 36 months, 3/20 (15%)]. Conclusions Re-administration of platinum-based chemotherapy for recurrent endometrial cancer may result in a long-term response exceeding the platinum-free interval in some patients. Even in the current situation, where immune checkpoint inhibitors have been introduced, re-administration of platinum-based chemotherapy is worth considering. |
| Keywords | Recurrent endometrial cancer
Re-administration of platinum-based chemotherapy
Platinum-free interval
Secondary platinum response
|
| Note | The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: http://dx.doi.org/10.1007/s10147-024-02585-1
|
| Published Date | 2024-07-13
|
| Publication Title |
International Journal of Clinical Oncology
|
| Volume | volume29
|
| Issue | issue10
|
| Publisher | Springer Science and Business Media LLC
|
| Start Page | 1594
|
| End Page | 1601
|
| ISSN | 1341-9625
|
| NCID | AA11086579
|
| Content Type |
Journal Article
|
| language |
English
|
| OAI-PMH Set |
岡山大学
|
| Copyright Holders | © The Author(s) 2024
|
| File Version | publisher
|
| PubMed ID | |
| DOI | |
| Web of Science KeyUT | |
| Related Url | isVersionOf https://doi.org/10.1007/s10147-024-02585-1
|
| License | http://creativecommons.org/licenses/by/4.0/
|
| Citation | Nagao, S., Nishio, S., Takehara, K. et al. Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study. Int J Clin Oncol 29, 1594–1601 (2024). https://doi.org/10.1007/s10147-024-02585-1
|
| Funder Name |
Okayama University
Sankai Gynecologic Study Group
|
